Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun Enters $125 Million China Deal for Ardelyx IBS Treatment

publication date: Dec 11, 2017

Fosun Pharma obtained China rights to tenapanor, an Ardelyx treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement. Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease. Ardelyx, a San Francisco area company, has completed US Phase III trials in which tenapanor met efficacy endpoints in both indications. The company describes the candidate as an oral, minimally systemic NHE3 inhibitor, and it expects to file for US approval next year. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: ARDX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.